Tirzepatide
Also known as: Mounjaro · Zepbound · Dual GIP/GLP-1 Agonist
Tirzepatide is a dual GIP/GLP-1 receptor agonist with the strongest weight-management and metabolic biomarker effects currently available. Provider-reviewed initiation, lean-mass preservation, and biomarker recalibration are standard.
Co-activates GIP and GLP-1 receptors, producing additive effects on insulin secretion, glucagon suppression, gastric emptying, and central satiety signaling.
What you need to know
Tirzepatide differs from pure GLP-1 receptor agonists by co-activating GIP, an incretin that amplifies insulin response and appears to support more favorable body-composition outcomes. In head-to-head data tirzepatide outperforms semaglutide on weight loss and A1C reduction. The same provider-reviewed framework applies: standardized biomarker panel at baseline, resistance-training and protein-intake guidance, microdose strategies where appropriate, and recalibration on a defined cadence.
How this entity relates
Every entity in the oMeds knowledge graph cross-links to the conditions, biomarkers, medications, and educational surfaces it touches.
Monitoring biomarkers
Bring this entity into your optimization pathway
Every condition, symptom, biomarker, and medication on oMeds is reviewed by a licensed provider and recalibrated against the standardized biomarker panel.